K
Kifa Therapeutics is a preclinical biotechnology company developing first-in-class small-molecule therapies for genetically defined Parkinson’s disease. The company's lead program focuses on a highly selective inhibitor targeting the G2019S mutation in the LRRK2 gene to slow disease progression. This precision neuroscience approach aims to deliver disease-modifying treatments through advanced translational research.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Kifa Therapeutics is a preclinical biotechnology company developing first-in-class small-molecule therapies for genetically defined Parkinson’s disease. Their lead program focuses on a highly selective inhibitor targeting the G2019S mutation in the LRRK2 gene to slow disease progression. The company utilizes a precision neuroscience approach to advance translational research toward disease-modifying treatments.